key: cord-0427901-3fw4fh28
authors: Rezel-Potts, E.; Douiri, A.; Sun, X.; Chowienczyk, P. J.; Shah, A. M.; Gulliford, M. C.
title: Differential impact of Covid-19 on incidence of diabetes mellitus and cardiovascular diseases in acute, post-acute and long Covid-19: population-based cohort study in the United Kingdom
date: 2021-12-14
journal: nan
DOI: 10.1101/2021.12.13.21267723
sha: 6891da727d1d6f3f591699c464a4fbfe87f97bcb
doc_id: 427901
cord_uid: 3fw4fh28

Objective: This study aimed to estimate the incidence of new diabetes mellitus (DM) and cardiovascular diseases (CVD) up to one year after Covid-19 compared with matched controls. Methods: A cohort study was conducted using electronic records for 1,473 family practices with a population of 14.9 million. Covid-19 patients without DM or CVD were individually matched with controls and followed up to October 2021. A difference-in-difference analysis estimated the net effect of Covid-19 allowing for baseline differences and covariates. Results: There were 372,816 Covid-19 patients, with 2,935 CVD and 3,139 DM events, and 372,816 matched controls with 1,193 CVD and 1,861 DM events following the index date. Net incidence of DM increased in acute Covid-19 up to four weeks from index date (adjusted rate ratio, RR 1.71, 1.40 to 2.10) and remained elevated in post-acute (five to 12 weeks from index date; RR 1.17, 1.01 to 1.36) and long-Covid-19 (13 to 52 weeks, 1.20, 1.09 to 1.31). Acute Covid-19 was associated with net increased CVD incidence (RR 6.02, 95% confidence interval 4.84 to 7.47) including pulmonary embolism (RR 14.5, 7.72 to 27.4), atrial arrythmias (6.58, 3.78 to 11.4) and venous thromboses (5.44, 3.22 to 9.17). CVD incidence declined in post-acute Covid-19 (R 1.68, 1.41 to 2.01) and showed no net increase in long Covid-19 (0.95, 0.85 to 1.06). Conclusions: DM incidence remains elevated up to one year following Covid-19. CVD is increased early after Covid-19 mainly from pulmonary embolism, atrial arrhythmias and venous thromboses.

Covid-19 is increasingly recognised as a multi-system condition. 1 Infection of the respiratory tract by the SARS-CoV-2 virus triggers host immune responses that may have systemic effects through activation of inflammatory pathways. 2, 3 Covid-19 may trigger a proinflammatory 'cytokine storm' with dysregulated immune response, platelet activation, hypercoagulability, endothelial cell dysfunction and thromboembolism affecting diverse systems with potential for end-organ damage. 4 Acute Covid-19 infection has been associated with new-onset cardiovascular disease (CVD) and diabetes mellitus (DM.)

Cardiac manifestations of Covid-19 5, 6 include cardiac injury with elevated troponin levels, heart failure and increased risk of mortality among patients hospitalised with Covid-19. 7, 8 Covid-19 may also be associated with acute myocardial infarction and ischaemic stroke in the first 4 weeks. 9 New onset hyperglycaemia has been reported in Covid-19 patients and is associated with worse prognosis. Complications of both pre-existing and new onset DM have been observed, including diabetic ketoacidosis and hyperosmolarity. [10] [11] [12] Possible mechanisms appear to be direct pancreatic damage from SARS-CoV-2 and/or the associated systemic inflammatory syndrome with severe Covid-19, as reflected in high levels of interleukin-6 (IL-6) and tumour necrosis factor alpha [TNFα], causing impaired pancreatic insulin secretion 13 and insulin resistance. 14 Since the first evidence of Covid-19 emerged in the beginning of 2020, there have been multiple waves of infection. There were in excess of 1,000 deaths per day in the UK during April 2020 and January 2021 with many more suffering illness of varying severity. 15 The longer-term outcomes of Covid-19 are now receiving increasing attention. A high proportion of patients report experiencing symptoms continuing for more than 4 weeks after initial presentation with Covid- 19 . 16 The distinction has been made between 'acute Covid-19' in the first four weeks after infection; 'post-acute' Covid-19 (or 'ongoing symptomatic covid-19'), . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.13.21267723 doi: medRxiv preprint from 5 to 12 weeks after the first infection; and 'long' Covid-19 (or 'post-covid-19 syndrome') with symptoms persisting more than 12 weeks after infection. 17 There is concern that cardiovascular and metabolic outcomes may be compromised in the aftermath of infection. However, susceptibility to and severity of Covid-19 infection is known to be associated with cardiometabolic risk. Furthermore, public health restrictions during the height of the pandemic, including 'lockdowns' or 'stay at home' orders, were associated with profound changes in diet, exercise habits and other health-related behaviours that might have impacted on cardiovascular disease and diabetes in the general population even in the absence of Covid-19 infection. Controlled studies are therefore needed to evaluate the net long-term impacts of Covid-19 infection on cardiovascular and diabetes outcomes after allowing for pre-morbid differences between cases and controls and changes over time in control participants. However, few studies have reported on long-term follow-up for large population-based samples.

Longitudinal datasets from electronic health records offer opportunities to analyse longer- 

The CPRD Aurum is a large database which includes comprehensive medical record data for a total of 1,473 family practices in England with approximately 14.9 million currently registered patients. 18 The data, which cover approximately 13% of the population of England, are representative of the general population with regards to geographical distribution, deprivation, age and gender. control patients with prevalent CVD or DM, diagnosed within 12 months of the start of record or more than 12 months before the index date, were excluded.

The study outcomes were first CVD and DM diagnoses. CVD diagnoses were grouped into the categories: myocardial infarction and ischaemic heart disease; atrial arrhythmias, including atrial fibrillation and supraventricular tachycardia; heart failure; cardiomyopathy and . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint phenotype if they were aged 35 years or less at diagnosis and were prescribed insulin within 91 days of diagnosis. 19 Mortality was evaluated from the CPRD date of death.

Covariates were defined using data recorded in the study period before the index date. included slightly more of 'Asian' ethnicity, fewer current smokers, more who were overweight . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.13.21267723 doi: medRxiv preprint and obese, and more with comorbidity than controls, while blood pressure distributions appeared to be similar. Figure 1 shows the incidence of DM and CVD from 52 weeks before the index date to 52 weeks after for Covid-19 cases (red) and controls (blue). In the period before the index date, the incidence of diabetes was slightly higher in patients who went on to be diagnosed with Covid-19 than control participants; a similar difference was also observed for the incidence of cardiovascular diseases. In the first four weeks after Covid-19 diagnosis, there was a sharp increase in the incidence of diabetes and an even greater increase in cardiovascular diseases. The increase in CVD diagnoses was apparent in the last estimate for the pre-index period, which might imply that Covid-19 associated CVD might be recorded before Covid-19

diagnoses. In the remainder of the first year following Covid-19 diagnosis, the incidence of diabetes mellitus remained elevated for Covid-19 cases while CVD incidence declined to pre-morbid values. Table 2 shows the incidence of DM and CVD aggregated into four periods: before the index date, within four weeks of the index date, from five to 12 weeks after the index date, and from 13 to 52 weeks after the index date. In the period before the index date, the incidence of diabetes was 13.73 (95% confidence interval 13.21 to 14.26) per 100,000 patient weeks in patients who were later diagnosed with Covid-19 but 10.10 (9.66 to 10.56) in controls who did not develop Covid-19; the incidence of CVD was 11.44 (10.96 to 11.93) per 100,000 patient weeks for cases and 6.72 (6.36 to 7.10) for controls respectively. During the first four weeks from Covid-19 diagnosis, the incidence of DM increased to 21.67 (19.40 to 24.12) and the incidence of CVD increased to 64.28 (60.33 to 68.42) per 100,000 patient weeks. In the post-acute and long Covid-19 periods, the incidence of CVD declined to 18.01 (16.53 to 19 .58) and 11.04 (10.47 to 11.64) per 100,000 patient weeks respectively. Thus, in the long-. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.13.21267723 doi: medRxiv preprint Covid period overall, the incidence of CVD declined to pre-morbid levels. During the same periods, the incidence of DM remained elevated at 18.37 (16.88 to 19.96) per 100,000 in the post-acute period and 17.73 (17.00 to 18.48) per 100,000 in the long-Covid period. Figure 2 shows the incidence of categories of cardiovascular disease from 52 weeks before the Covid-19 index date to 52 weeks after. Pulmonary embolism showed the greatest increase during the acute Covid-19 period, with 29.93 cases per 100,000 patient weeks. The value was approximately three times higher than for atrial arrhythmias (9.95 per 100,000 per week) or venous thrombosis (8.65 per 100,000 per week); five times higher than for myocardial infarction and ischaemic heart disease (5.66 per 100,000 per week) or stroke (5.33 per 100,000 per week); and nearly than ten-times higher than the increase in heart failure (2.93 per 100,000 per week) or cardiomyopathy and myocarditis (1.56 per 100,000) .

While the relative effects differed for categories of CVD, the time course of changes in incidence was similar for each category of cardiovascular disease. Table 3 presents estimated incidence rate ratios adjusted for age, gender, ethnicity, smoking, body mass index, systolic blood pressure and Charlson comorbidity score. After allowing for underlying differences between cases and controls, and between the baseline pre-index period and follow-up, the net effect of acute Covid-19 on CVD incidence was estimated to be an adjusted rate ratio of 6.02 (95% confidence interval 4.84 to 7.47), while for DM incidence the adjusted rate ratio was 1.71 (1.40 to 2.10). In the post-acute Covid-19 period, the adjusted incidence rate ratio for CVD declined to 1.68 (1.41 to 2.01), while for DM in was 1.17 (1.01 to 1.36). In the long Covid-19 period, the adjusted incidence rate ratio for CVD was 0.95 (0.85 to 1.06) while for DM this remained elevated at 1.20 (1.09 to 1.31). In control participants, the incidence of CVD showed no overall change following the index date but there was evidence that the incidence of DM in controls was slightly higher for periods . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 2 ).

When categories of CVD were analysed separately (Table 3) There was some evidence that cardiomyopathy and myocarditis might be more frequent in the post-acute period (3.26, 1.30 to 8.15) than in the acute illness. There was no evidence that any of these categories of CVD showed a net increase during the long-Covid-19 period. 

Drawing on longitudinal electronic health records from primary care, this study compared Covid-19 patients with matched population controls from one year before a Covid-19 diagnosis to one year after. The study showed that patients recorded with Covid-19 in primary care are at slightly greater risk of CVD and DM even before the Covid-19 diagnosis.

These elevated risks were associated with higher body mass index, greater comorbidity and a higher proportion of 'Asian' ethnicity. After allowing for baseline differences between Covid-19 patients and controls, new DM diagnoses increased 1.7-fold during acute Covid-19 and remained elevated during both post-acute and long Covid-19. There was evidence of increased glucocorticoid exposure in Covid-19 patients, but this might be associated with only a very small proportion of new DM events. New CVD events were increased more than six-fold during acute Covid-19 and more than 50% in post-acute Covid-19. This increase was largely driven by pulmonary embolism diagnoses, but atrial arrythmias, venous thrombosis, myocardial infarction, stroke and heart failure also showed more modest . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

The long-term outcomes of Covid-19 infection represent an emerging area of research and public concern, but definitions are not universally agreed. This study drew on clinical recommendations that distinguish 'acute' (four weeks), 'post-acute' (three months) and 'long'

(one year) periods after Covid-19 infection. 17 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint A possible effect of SARS-CoV-2 infection on pancreatic function is suggested by the finding that the virus infects pancreatic beta cells, 28 reduces insulin production and promotes betacell apoptosis. 29 However, Covid-19 may also lead to reduced physical activity and deconditioning 30 leading to greater insulin resistance. Contacts with medical care may also lead to increased opportunities to detect previously undiagnosed diabetes. Previous studies have often reported hospital-based cohorts, with smaller samples or shorter durations of follow-up. This large population-based study shows that patients diagnosed with Covid-19 have a slightly higher baseline risk of diabetes mellitus. There is evidence that new-onset diabetes is increased during the acute Covid-19 illness and there is evidence that a net increase in diabetes persists for at least 12 months following the Covid-19 illness. Analysis of electronic records does not permit unequivocal distinction of type I and type II diabetes phenotypes. There was evidence that patients diagnosed during the acute illness might be more likely to be prescribed insulin but there was no evidence for increased type I diabetes overall, nor was there evidence that glucocorticoid exposure might account for a high proportion of cases.

This study drew on a large, longitudinal population-based data resource that enabled us to conduct a matched analysis of mortality and new CVD and DM diagnoses for up to one year following Covid-19.

[28] The study drew on clinical records with several limitations. We included patients with both confirmed and suspected Covid-19, but a sensitivity analysis found that restricting the analysis to PCR confirmed infections would not alter conclusions.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.13.21267723 doi: medRxiv preprint However, PCR testing was associated with patient characteristics and reliance on PCR confirmation for participant selection might lead to bias. The database enabled adjustment for a range of important covariates, but these were not always completely recorded. This may reflect that this was a relatively young to middle-aged cohort lacking in long-term conditions that would warrant regular consultations and monitoring. In health records, values are commonly missing 'not at random' making the application of imputation methods more difficult. We did not include a measure of deprivation, which is associated both with diabetes and cardiovascular disease, but cases and controls were matched for family practice, providing partial control for area-based measures including deprivation. Analyses did not include measures of the severity of illness in Covid-19. However, the concept of 'severity' might be difficult to operationalise in a study of Covid-19 complications because a greater number of complications might be indicative of more severe illness. We did not have access to data for secondary care prescribing, consequently exposure to glucocorticoids might be under-estimated. 18 The observational nature of the study limits causal inferences concerning whether the increased risk of new CVD and DM diagnoses may result from Covid-19, or whether undiagnosed CVD and DM were more prevalent among Covid-19 cases, or whether Covid-19 aggravated or altered the natural history of pre-existing disease.

This study provides evidence that DM incidence remains elevated for up to one year following Covid-19 infection. Future studies should aim to characterise the phenotypic characteristics and underlying mechanisms of Covid-19 associated diabetes mellitus. Advice to patients recovering from Covid-19 should include measures to reduce diabetes risk, including diet, weight management and physical activity levels. CVD is increased early after Covid-19 infection, mainly from pulmonary embolism, atrial arrhythmias and venous thromboses, and the risk is increased for up to three months. Future research should . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.13.21267723 doi: medRxiv preprint determine which patients are at greatest risk, and whether these cardiovascular complications may be prevented through prophylactic measures.

Ethical approval: The protocol was given scientific and ethical approval by the CPRD Independent Scientific Advisory Committee (ISAC protocol 20_00265R). CPRD holds overarching research ethics committee approval for the conduct of research using fully anonymised electronic health records data from the CPRD databases.

The study protocol has been published in summary form by the CPRD/MHRA and can be accessed here. to the corresponding author at martin.gulliford@kcl.ac.uk. All proposals requesting data access will require approval from CPRD before data release.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q q 

Long covid-mechanisms, risk factors, and management

Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19-systematic review, meta-analysis, and meta-regression

Factors associated with COVID-19-related death using OpenSAFELY

Cardiovascular manifestations of COVID-19 infection

Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome

Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a selfcontrolled case series and matched cohort study

COVID-19 infection may cause ketosis and ketoacidosis

Diabetic ketoacidosis precipitated by COVID-19: A report of two cases and review of literature

New-Onset Diabetes in COVID-19: Time to Frame Its Fearful Symmetry

Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics

nfectionintheuk/2september2021 accessed 10th

Managing the long-term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline

Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum

Trends in Type 1 diabetes incidence in the UK in 0-to 14-year-olds and in 15-to 34-year-olds

A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation

Adaptation and validation of the Charlson Index for Read/OXMIS coded databases

Attributes and predictors of long COVID